PMN:TSX; ARFXF:OTCQB

ProMIS Neurosciences Inc.

ProMIS Neurosciences is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSE’s are misfolded regions on otherwise normal proteins. In the infectious disease setting, these disease-specific epitopes represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19.
PMN:TSX ARFXF:OTCQB

Expert Comments:

ProMIS Neurosciences states that the current version of the ProMIS-BCNI assay achieves 99.9% sensitivity and 99.5% specificity for SARS CoV-2, the coronavirus causing COVID-19.
read more >
Testing and validation of ProMIS Neurosciences' antibody targets will be conducted over the coming weeks.
read more >
ProMIS is harnessing its unique technology platform to develop a more error-free antibody test.
read more >
ProMIS Neurosciences reported it has generated novel intrabodies that are highly selective for misfolded forms of TAR DNA-binding protein 43 implicated in several neurologic disorders.
read more >

Cosme Ordonez, Noble Capital Markets

(4/20/20)
"ProMIS Neurosciences Inc. announced a collaboration to develop a sensitive and specific laboratory test to detect antibodies against SARS-CoV-2, the virus causing Covid-19. Given ProMIS' experience with peptide and antibody based technologies, we believe the company and its collaborators will be able to develop a specific test without cross-reactivity with other viruses in the coronavirus family. Thus far, high test specificity has been a challenge for the industry. . . In our opinion, ProMIS could potentially attract a big pharmaceutical company to sign a partnership to advance development of vectorization technology."

Cosme Ordonez, Noble Capital Markets

(8/14/19)
"In Q2/19, ProMIS Neurosciences Inc. identified several antibody drug candidates targeting the protein tau, which is a primary pharmaceutical target for the treatment of Alzheimer's disease. . .the company has now developed antibodies against toxic oligomers derived from two primary Alzheimer's targets, tau and amyloid beta. In addition, ProMIS' drug portfolio includes antibodies against alpha-synuclein and TDP43 proteins for the treatment of Parkinson's disease and amyotrophic lateral sclerosis, respectively."

Cosme Ordonez, Noble Capital Markets

(7/23/19)
"ProMIS Neurosciences Inc.'s currently deflated share price does not reflect the potential of the company's lead drug PMN310. In our opinion, its preclinical results could lure a larger company to sign a high value partnership, which could act as a positive catalyst for the shares."

More Expert Comments


The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Unique tech. platform creates highly selective antibodies for root cause of Alzheimer’s, ALS and Parkinson’s
 
2nd generation PMN 310, anticipated to show significant advantages in efficacy & safety vs Biogen’s 1st to market aducanumab in Alzheimer’s
 
Unique platform supports development of highly sensitive & specific blood test for antibodies specific for COVID-19
catalyst Calendar
Q2
2020
Potential successful serological antibody test for COVID-19 (end June 2020); expansion of current co
Q2
2020
Potential collaborations with pharma partners/patient associations forALS, Parkinson’s disease (comi
Q3
2020
Anticipated approval of Biogen’s aducanumab for AD, rolling BLA ongoing, news expected around end Q3